Atrium Biotechnologies, Inc. has acquired the assets of London, Ontario-based Douglas Laboratories Canada (DL Canada). DL Canada has been marketing Douglas Laboratories products in Canada since 2000 and has current annual revenues of approximately $5 million. DL Canada’s current management and staff are staying on to ensure the successful integration of the two companies. “This acquisition provides Atrium with a platform to develop the Canadian healthcare professional market...